Results 121 to 130 of about 177,264 (261)

Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks.

International journal of clinical practice, 2010
Counterfeit drugs are inherently dangerous and a growing problem; counterfeiters are becoming increasingly sophisticated. Growth of the counterfeit medication market is attributable in part to phosphodiesterase type 5 inhibitor (PDE5i) medications for erectile dysfunction (ED).
Jackson, G, Arver, S, Banks, I, Stecher, V J   +3 more
openaire   +2 more sources

Are phosphodiesterase Type 5 inhibitors potential therapies for Alzheimer's disease and related dementias? [PDF]

Brain Commun, 2022
Newby D.
europepmc   +1 more source

HSD37 Phosphodiesterase Type 5 Inhibitors Prescriber Analysis: Recent Results from US Commercial Population [PDF]

, 2023
Kathryn Morris, Sirikan Rojanasarot
openalex   +1 more source

Combination vardenifil and tadalifil drug induced liver injury; case report and review of the literature of liver injury associated with phosphodiesterase type 5 inhibitors. [PDF]

Can Liver J, 2023
Xu B, Braxton DR, Fong TL.
europepmc   +1 more source

Scaffold Repurposing Reveals New Nanomolar Phosphodiesterase Type 5 (PDE5) Inhibitors Based on Pyridopyrazinone Scaffold: Investigation of In Vitro and In Silico Properties [PDF]

, 2022
Kamelia M. Amin, Ossama M. El-Badry, Doaa E. Abdel Rahman, Magda H. Abdellattif, Mohammed A. S. Abourehab, Mahmoud El‐Maghrabey, Fahmy G. Elsaid, Mohamed A. El Hamd, Ahmed Elkamhawy, Usama M. Ammar   +9 more
openalex   +1 more source

Do phosphodiesterase type 5 inhibitors increase the risk of biochemical recurrence after radical prostatectomy?

European Urology Open Science, 2023
J.P. Mulhall, J.M.F. Flores, A.V Vickers, P.T.S Scardino   +3 more
doaj   +1 more source

Safety profile and signal detection of phosphodiesterase type 5 inhibitors for erectile dysfunction: a Food and Drug Administration Adverse Event Reporting System analysis. [PDF]

Sex Med, 2023
Shin YE, Rojanasarot S, Hincapie AL, Guo JJ.   +3 more
europepmc   +1 more source

Non-Arteritic Anterior Ischemic Optic Neuropathy Associated With the Use of Phosphodiesterase Type 5 Inhibitors: A Literature Review. [PDF]

Cureus, 2022
Hor M, Baradeiya AM, Qasim H, Nasr M, Mohammad A.   +4 more
europepmc   +1 more source

MP80-01 PHOSPHODIESTERASE TYPE 5 INHIBITOR USE IS NOT ASSOCIATED WITH BIOCHEMICAL RECURRENCE AFTER DEFINITIVE THERAPY FOR PROSTATE CANCER [PDF]

, 2016
Michael Leapman, Hao G. Nguyen, Janet E. Cowan, Sima P. Porten, Maxwell V. Meng, Matthew R. Cooperberg, Peter R. Carroll   +6 more
openalex   +1 more source

Effects of itraconazole and rifampicin on the pharmacokinetics and safety of youkenafil, a novel phosphodiesterase type 5 inhibitor, in healthy Chinese subjects

, 2022
Keli Wang, Juefang Ding, Xianjing Li, Wenjing Guo, Xingyu Zhu, Yue Su, Luning Sun, Huan Zhou, Li Ding   +8 more
openalex   +1 more source